\u0160odien, 29. novembr\u012b, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2018. gada devi\u0146u m\u0113ne\u0161u nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2018. gada devi\u0146os m\u0113ne\u0161os bija 102,4 milj. eiro, kas ir par 6,6 milj. eiro vai par 7% vair\u0101k nek\u0101 2017. gada devi\u0146os m\u0113ne\u0161os. Savuk\u0101rt koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2018. gada devi\u0146os m\u0113ne\u0161os bija 7,6 milj. eiro, kas, sal\u012bdzinot ar 2017. gada devi\u0146iem m\u0113ne\u0161iem, ir palielin\u0101jusies par 1,1 milj. eiro vai par 17%. 2018. gada devi\u0146os m\u0113ne\u0161os Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 82 pasaules valst\u012bm kopum\u0101 par 95,3 milj. eiro, kas ir par 6,5 milj. eiro vai par 7% vair\u0101k nek\u0101 2017. gada devi\u0146os m\u0113ne\u0161os.<\/p>\n\n\n\n
AS Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans: \u201eSasniegtie rezult\u0101ti apliecina, ka farm\u0101cijas biznes\u0101 stabila aug\u0161upeja ir sasniedzama ar p\u0101rdom\u0101tu strat\u0113\u0123iju un eksporta apjomu audz\u0113\u0161anu. M\u0113s stiprin\u0101m savas tirgus poz\u012bcijas, pateicoties koncerna sabiedr\u012bbu sekm\u012bgai darb\u012bbai starptautisk\u0101 ar\u0113n\u0101.\u201d<\/p>\n\n\n\n
Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2018. gada devi\u0146os m\u0113ne\u0161os bija 95,8 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot ar 2017. gada devi\u0146iem m\u0113ne\u0161iem, par 6,1 milj. eiro vai 7%. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2018. gada devi\u0146os m\u0113ne\u0161os sasniedza 61,1 milj. eiro, kas ir par 2,1 milj. eiro vai par 4% vair\u0101k nek\u0101 2017. gada devi\u0146os m\u0113ne\u0161os. Sal\u012bdzinot ar 2017. gada devi\u0146iem m\u0113ne\u0161iem, 2018. gada devi\u0146os m\u0113ne\u0161os iev\u0113rojam\u0101kais p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Uzbekist\u0101n\u0101 par 29%, Kirgizst\u0101n\u0101 par 24%, Kazahst\u0101n\u0101 par 18%, Arm\u0113nij\u0101 par 14%, Azerbaid\u017e\u0101n\u0101 un Baltkrievij\u0101 par 9%, Ukrain\u0101 par 7%.<\/p>\n\n\n\n
Gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs 2018. gada devi\u0146os m\u0113ne\u0161os sasniedza 32,4 milj. eiro, kas ir par 4,3 milj. eiro vai 15% vair\u0101k nek\u0101 2017. gada devi\u0146os m\u0113ne\u0161os. P\u0101rdo\u0161anas apjoms 2018. gada devi\u0146os m\u0113ne\u0161os, sal\u012bdzinot ar 2017. gada devi\u0146iem m\u0113ne\u0161iem, Polij\u0101 ir palielin\u0101jies 4,1 reizes, \u010cehij\u0101 un Horv\u0101tij\u0101 2,2 reizes, D\u0101nij\u0101 un Zviedrij\u0101 par 84%, Somij\u0101 par 58%, un Sp\u0101nij\u0101 par 43%.<\/p>\n\n\n\n
2018. gada devi\u0146os m\u0113ne\u0161os akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 5,7 milj. eiro, kas ir par 0,45 milj. eiro vai 9% vair\u0101k nek\u0101 2017. gada devi\u0146os m\u0113ne\u0161os. \u0160aj\u0101 period\u0101 liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tika veikts uz ES valst\u012bm, Jap\u0101nu, ASV un Austr\u0101liju. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2018. gada devi\u0146os m\u0113ne\u0161os bija deksmedetomid\u012bns, zopiklons, pimobend\u0101ns, oksitoc\u012bns, medetomid\u012bns, ftoraf\u016brs, antipamezols, detomid\u012bns.<\/p>\n\n\n\n
AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eGrindeks koncerna darb\u012bbas rezult\u0101ti 2018. gada devi\u0146os m\u0113ne\u0161os uzr\u0101da stabilu pieaugumu, kas v\u0113rojams gan gatavo z\u0101\u013cu, gan akt\u012bvo farmaceitisko vielu realiz\u0101cij\u0101. Efekt\u012bvas m\u0101rketinga un p\u0101rdo\u0161anas aktivit\u0101tes, k\u0101 ar\u012b koncentr\u0113\u0161an\u0101s uz kompleksiem risin\u0101jumiem pacientu vajadz\u012bbu apmierin\u0101\u0161anai pal\u012bdz\u0113s nodro\u0161in\u0101t pieaugumu ar\u012b turpm\u0101k.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
\u0160odien, 29. novembr\u012b, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2018. gada devi\u0146u m\u0113ne\u0161u nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2018. gada devi\u0146os m\u0113ne\u0161os…<\/p>\n","protected":false},"author":3,"featured_media":2312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=2315"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2315\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/2312"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=2315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=2315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=2315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}